Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the third-leading cause of cancer-related deaths worldwide. Curative intent treatment options for patients with HCC include liver transplantation, resection and ablation of small lesions. Other potentially curative...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/6/1748 |
| _version_ | 1797612984948752384 |
|---|---|
| author | Perla Chami William Jarnagin Ghassan K. Abou-Alfa James Harding Neal Kim Haibo Lin Maria El Homsi Christopher Crane Carla Hajj |
| author_facet | Perla Chami William Jarnagin Ghassan K. Abou-Alfa James Harding Neal Kim Haibo Lin Maria El Homsi Christopher Crane Carla Hajj |
| author_sort | Perla Chami |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the third-leading cause of cancer-related deaths worldwide. Curative intent treatment options for patients with HCC include liver transplantation, resection and ablation of small lesions. Other potentially curative therapies include cryoablation, microwave ablation and percutaneous alcohol injection. For locally advanced disease, different arterially directed therapies including transarterial chemoembolization and selective internal radiation therapy, plus external beam radiation including three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, stereotactic body radiation therapy and proton beam therapy, are available or studied. Systemic therapies based on checkpoint inhibitors and tyrosine kinase inhibitors are available for the management of metastatic HCC and sometimes for locally advanced disease. Combinations of locoregional therapies with systemic drugs are currently the subject of several clinical trials. |
| first_indexed | 2024-03-11T06:48:35Z |
| format | Article |
| id | doaj.art-59c050af4ef849db840752412d1117f0 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T06:48:35Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-59c050af4ef849db840752412d1117f02023-11-17T10:06:39ZengMDPI AGCancers2072-66942023-03-01156174810.3390/cancers15061748Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular CarcinomaPerla Chami0William Jarnagin1Ghassan K. Abou-Alfa2James Harding3Neal Kim4Haibo Lin5Maria El Homsi6Christopher Crane7Carla Hajj8Department of Biology, Faculty of Arts and Sciences, American University of Beirut, Beirut 1107, LebanonMemorial Sloan Kettering Cancer Center, New York, NY 10027, USAMemorial Sloan Kettering Cancer Center, New York, NY 10027, USAMemorial Sloan Kettering Cancer Center, New York, NY 10027, USAMemorial Sloan Kettering Cancer Center, New York, NY 10027, USANew York Proton Center, New York, NY 10035, USAMemorial Sloan Kettering Cancer Center, New York, NY 10027, USAMemorial Sloan Kettering Cancer Center, New York, NY 10027, USAMemorial Sloan Kettering Cancer Center, New York, NY 10027, USAHepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the third-leading cause of cancer-related deaths worldwide. Curative intent treatment options for patients with HCC include liver transplantation, resection and ablation of small lesions. Other potentially curative therapies include cryoablation, microwave ablation and percutaneous alcohol injection. For locally advanced disease, different arterially directed therapies including transarterial chemoembolization and selective internal radiation therapy, plus external beam radiation including three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, stereotactic body radiation therapy and proton beam therapy, are available or studied. Systemic therapies based on checkpoint inhibitors and tyrosine kinase inhibitors are available for the management of metastatic HCC and sometimes for locally advanced disease. Combinations of locoregional therapies with systemic drugs are currently the subject of several clinical trials.https://www.mdpi.com/2072-6694/15/6/1748hepatocellular carcinomacombination therapyablationinterventional radiologyablative radiation therapychemoembolization |
| spellingShingle | Perla Chami William Jarnagin Ghassan K. Abou-Alfa James Harding Neal Kim Haibo Lin Maria El Homsi Christopher Crane Carla Hajj Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma Cancers hepatocellular carcinoma combination therapy ablation interventional radiology ablative radiation therapy chemoembolization |
| title | Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma |
| title_full | Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma |
| title_fullStr | Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma |
| title_full_unstemmed | Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma |
| title_short | Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma |
| title_sort | non surgical locoregional therapies alone or in combination with systemic therapy in patients with hepatocellular carcinoma |
| topic | hepatocellular carcinoma combination therapy ablation interventional radiology ablative radiation therapy chemoembolization |
| url | https://www.mdpi.com/2072-6694/15/6/1748 |
| work_keys_str_mv | AT perlachami nonsurgicallocoregionaltherapiesaloneorincombinationwithsystemictherapyinpatientswithhepatocellularcarcinoma AT williamjarnagin nonsurgicallocoregionaltherapiesaloneorincombinationwithsystemictherapyinpatientswithhepatocellularcarcinoma AT ghassankaboualfa nonsurgicallocoregionaltherapiesaloneorincombinationwithsystemictherapyinpatientswithhepatocellularcarcinoma AT jamesharding nonsurgicallocoregionaltherapiesaloneorincombinationwithsystemictherapyinpatientswithhepatocellularcarcinoma AT nealkim nonsurgicallocoregionaltherapiesaloneorincombinationwithsystemictherapyinpatientswithhepatocellularcarcinoma AT haibolin nonsurgicallocoregionaltherapiesaloneorincombinationwithsystemictherapyinpatientswithhepatocellularcarcinoma AT mariaelhomsi nonsurgicallocoregionaltherapiesaloneorincombinationwithsystemictherapyinpatientswithhepatocellularcarcinoma AT christophercrane nonsurgicallocoregionaltherapiesaloneorincombinationwithsystemictherapyinpatientswithhepatocellularcarcinoma AT carlahajj nonsurgicallocoregionaltherapiesaloneorincombinationwithsystemictherapyinpatientswithhepatocellularcarcinoma |